AUA 2021: Primary Chemoablation of Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (OPTIMA II): A Phase 2b, Open-Label, Single-Arm Trial

AUA 2021 efficacy and safety of UGN-102, a mitomycin-containing reverse thermal gel, primary chemoablative therapy in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.

Read the full article here

Related Articles